Drug Type Bispecific antibody |
Synonyms AP-505, B 1962, B-1962 |
Target |
Mechanism PDL1 inhibitors(Programmed death-ligand 1 inhibitors), VEGF inhibitors(Vascular endothelial growth factor inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 2 | CN | 07 Nov 2024 | |
Solid tumor | Preclinical | CN | - |